<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518191</url>
  </required_header>
  <id_info>
    <org_study_id>JTU-6H-20150731001</org_study_id>
    <nct_id>NCT02518191</nct_id>
  </id_info>
  <brief_title>Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity</brief_title>
  <official_title>Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangyun Zong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Peace Maternity and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized controlled study is conducted to analyze the effect of Goserelin
      on ovarian function in women with breast cancer in China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of ovarian failure</measure>
    <time_frame>5 years</time_frame>
    <description>Composition of antimüllerian hormone；number of ovarian follicles；menses return</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of pregnancy and delivery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GnRHa group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>None GnRHa group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHa</intervention_name>
    <description>3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.</description>
    <arm_group_label>GnRHa group</arm_group_label>
    <other_name>goserelin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women 18 to 49 years of age are eligible for enrollment

          -  Patients have operable stage I to IIIA breast cancer for which treatment with adjuvant
             or neoadjuvant cyclophosphamide-containing chemotherapy was planned.

          -  Eligible participants had taken no estrogens, antiestrogens, selective
             estrogen-receptor modulators, aromatase inhibitors, or hormonal contraceptives within
             the month before enrollment.

          -  Human chorionic gonadotropin negative by urine test before entering the group.

          -  Informed consent, understanding and compliance with the requirements of the study.

          -  No significant chronic disease and any organ dysfunction.

        Exclusion Criteria:

          -  Exceptions were made for the use of hormonal contraception in women younger than 35
             years of age that was discontinued before randomization.

          -  Use of hormonal treatment for up to 2 months for the purposes of in vitro
             fertilization and cryopreservation of embryos or oocytes before randomization.

          -  Patients with metastatic lesions or history of bilateral ovariectomy,ovarian radiation
             were excluded.

          -  Patients received previous adjuvant endocrine therapy for breast cancer are not
             suitable to this trial.

          -  Patients with uterine and/or adnexal diseases needing medical or surgical treatment
             are not suitable.

          -  Allergic to active or inactive excipients of GnRHa is an exclusion criterion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XIANGYUN ZONG, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University affiliated 6th Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RUN HUANG, MD</last_name>
    <phone>+86(21)24058549</phone>
    <email>hapsyottahuang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>XIANGYUN ZONG, MD, PhD</last_name>
    <phone>+86(21)24058549</phone>
    <email>tigerzong@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Yu, MD</last_name>
      <email>yuyangkaiyu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiangming He, MD</last_name>
      <email>merchant001@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yang Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University Affiliated Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Run Huang, MD</last_name>
      <phone>15000035506</phone>
      <email>hapsyotta@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiangyun Zong, MD,PHD</last_name>
      <phone>+86(21)24058549</phone>
      <email>tigerzong@msn.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiangyun Zong, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R; ZIPP International Collaborators Group. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer. 2006 May;42(7):895-904. Epub 2006 Mar 20.</citation>
    <PMID>16545560</PMID>
  </reference>
  <reference>
    <citation>Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003 Aug;39(12):1711-7.</citation>
    <PMID>12888366</PMID>
  </reference>
  <reference>
    <citation>Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 1;23(25):5973-82. Epub 2005 Aug 8.</citation>
    <PMID>16087950</PMID>
  </reference>
  <reference>
    <citation>LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007 May 19;369(9574):1711-23.</citation>
    <PMID>17512856</PMID>
  </reference>
  <reference>
    <citation>Yang H, Zong X, Yu Y, Shao G, Zhang L, Qian C, Bian Y, Xu X, Sun W, Meng X, Ding X, Chen D, Zou D, Xie S, Zheng Y, Zhang J, He X, Sun C, Yu X, Ni J. Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial. Br J Cancer. 2013 Aug 6;109(3):582-8. doi: 10.1038/bjc.2013.324. Epub 2013 Jul 16.</citation>
    <PMID>23860520</PMID>
  </reference>
  <reference>
    <citation>Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr. 1997 Feb;130(2):210-6.</citation>
    <PMID>9042122</PMID>
  </reference>
  <reference>
    <citation>Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, Robison LL, Sklar CA. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006 May;91(5):1723-8. Epub 2006 Feb 21.</citation>
    <PMID>16492690</PMID>
  </reference>
  <reference>
    <citation>Green DM, Sklar CA, Boice JD Jr, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009 May 10;27(14):2374-81. doi: 10.1200/JCO.2008.21.1839. Epub 2009 Apr 13. Review.</citation>
    <PMID>19364956</PMID>
  </reference>
  <reference>
    <citation>Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):738-44.</citation>
    <PMID>15936554</PMID>
  </reference>
  <reference>
    <citation>Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007 Nov 15;110(10):2222-9.</citation>
    <PMID>17932880</PMID>
  </reference>
  <reference>
    <citation>Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999 Sep-Oct;6(5):229-39. Review.</citation>
    <PMID>10554760</PMID>
  </reference>
  <reference>
    <citation>Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007 Sep;12(9):1044-54. Review.</citation>
    <PMID>17914074</PMID>
  </reference>
  <reference>
    <citation>Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod. 2004 Jun;19(6):1294-9. Epub 2004 Apr 29.</citation>
    <PMID>15117898</PMID>
  </reference>
  <reference>
    <citation>Osborne SE, Detti L. GnRH-analogues for ovarian protection in childhood cancer patients: how adult hypotheses are relevant in prepubertal females. Curr Drug Targets. 2013 Jul;14(8):856-63. Review.</citation>
    <PMID>23614679</PMID>
  </reference>
  <reference>
    <citation>Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010 Feb;20(2):280-5. doi: 10.1016/j.rbmo.2009.11.010. Epub 2009 Dec 3.</citation>
    <PMID>20113967</PMID>
  </reference>
  <reference>
    <citation>Maltaris T, Beckmann MW, Binder H, Mueller A, Hoffmann I, Koelbl H, Dittrich R. The effect of a GnRH agonist on cryopreserved human ovarian grafts in severe combined immunodeficient mice. Reproduction. 2007 Feb;133(2):503-9.</citation>
    <PMID>17307918</PMID>
  </reference>
  <reference>
    <citation>Browne HN, Moon KS, Mumford SL, Schisterman EF, Decherney AH, Segars JH, Armstrong AY. Is anti-Müllerian hormone a marker of acute cyclophosphamide-induced ovarian follicular destruction in mice pretreated with cetrorelix? Fertil Steril. 2011 Jul;96(1):180-186.e2. doi: 10.1016/j.fertnstert.2011.04.008. Epub 2011 May 7.</citation>
    <PMID>21550044</PMID>
  </reference>
  <reference>
    <citation>Detti L, Uhlmann RA, Zhang J, Diamond MP, Saed GM, Fletcher NM, Lu M, Williams LJ. Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. Fertil Steril. 2014 Apr;101(4):1157-64.e1. doi: 10.1016/j.fertnstert.2013.12.028. Epub 2014 Jan 23.</citation>
    <PMID>24462062</PMID>
  </reference>
  <reference>
    <citation>Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.</citation>
    <PMID>25738668</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</investigator_affiliation>
    <investigator_full_name>Xiangyun Zong</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>GnRHa</keyword>
  <keyword>ovarian function</keyword>
  <keyword>anti-mullerian hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

